All Relations between Depressive Disorder and hmgb1
| Publication | Sentence | Publish Date | Extraction Date | Species |
|---|---|---|---|---|
| Ali Emre Köse, Tayfun Turan, Eser Kili. May high mobility group box protein-1 be a biomarker for major depressive disorder? Journal of neuroimmunology. vol 396. 2024-10-19. PMID:39426194. | high mobility group box protein-1 (hmgb1), which has proinflammatory properties, is known to be involved in psychiatric disorders as far as we know, there are only one clinical studies investigating the role of hmgb1 in major depressive disorder (mdd). | 2024-10-19 | 2024-10-22 | human |
| Kazue Hisaoka-Nakashima, Yuka Takeuchi, Yukino Saito, Takahisa Shimoda, Yoki Nakamura, Dengli Wang, Keyue Liu, Masahiro Nishibori, Norimitsu Moriok. Glucocorticoids induce HMGB1 release in primary cultured rat cortical microglia. Neuroscience. 2024-09-20. PMID:39304023. | stress, a risk factor for major depressive disorder and alzheimer disease, leads to the release of high-mobility group box-1 (hmgb1) protein, which in turn causes neuroinflammation. | 2024-09-20 | 2024-09-23 | rat |
| Bo Wang, Xiao Huang, Xiao Pan, Ting Zhang, Cheng Hou, Wen-Jun Su, Lin-Lin Liu, Jia-Mei Li, Yun-Xia Wan. Minocycline prevents the depressive-like behavior through inhibiting the release of HMGB1 from microglia and neurons. Brain, behavior, and immunity. vol 88. 2021-04-27. PMID:32553784. | our previous study reports the causal role of high mobility group box 1 (hmgb1) in the development of depression; and we find glycyrrhizic acid (gza) can be a potential treatment for major depressive disorder (mdd) considering its inhibition of hmgb1 activity. | 2021-04-27 | 2023-08-13 | Not clear |